PapersFlow Research Brief
Peripheral Neuropathies and Disorders
Research Guide
What is Peripheral Neuropathies and Disorders?
Peripheral Neuropathies and Disorders refer to a cluster of neurological conditions including Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy, characterized by autoimmune-mediated damage to peripheral nerves, often treated with intravenous immunoglobulin therapy.
This field encompasses 43,064 papers on the pathogenesis, diagnosis, treatment, and prognosis of autoimmune neuropathies associated with specific antibodies and infections. Research emphasizes the autoimmune nature of disorders like Guillain-Barré syndrome and polyneuropathy. Diagnostic approaches integrate clinical findings with imaging and serological markers for accurate identification.
Topic Hierarchy
Research Sub-Topics
Guillain-Barré Syndrome Pathogenesis
Studies molecular mimicry between Campylobacter jejuni lipooligosaccharides and gangliosides triggering anti-ganglioside antibodies. Focuses on axonal versus demyelinating variants.
Intravenous Immunoglobulin Therapy in GBS
Evaluates IVIg mechanisms, optimal dosing, and comparative efficacy against plasma exchange in acute GBS. Includes biomarker response correlations.
Chronic Inflammatory Demyelinating Polyneuropathy Diagnosis
Refines electrodiagnostic criteria, nerve biopsy findings, and CSF protein analysis for CIDP diagnosis. Addresses mimics and progression from acute neuropathies.
Autoantibodies in Peripheral Neuropathies
Characterizes anti-ganglioside, contactin, and neurofascin antibodies in GBS/CIDP variants. Correlates serology with clinical phenotypes and treatment response.
Prognosis and Long-term Outcomes in GBS
Identifies predictors of poor recovery, fatigue persistence, and neuropathic pain in GBS survivors. Longitudinal cohorts inform rehabilitation protocols.
Why It Matters
Peripheral neuropathies impact neurological function through demyelination and axonal damage, affecting patient mobility and sensory processing in conditions overlapping with central nervous system disorders. Thompson et al. (2017) in "Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria" provide criteria that aid differential diagnosis from mimicking peripheral conditions, with 7511 citations reflecting clinical utility. Wingerchuk et al. (2015) established "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders" distinguishing it from peripheral neuropathies via AQP4-IgG antibodies, guiding targeted therapies in 4307 cited works. These tools enable precise interventions, such as intravenous immunoglobulin for inflammatory polyradiculoneuropathy, improving prognosis in neurology clinics.
Reading Guide
Where to Start
"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria" by Thompson et al. (2017), as it offers the most recent, highly cited framework (7511 citations) for understanding diagnostic integration applicable to peripheral neuropathy differentials.
Key Papers Explained
McDonald et al. (2001) "Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis" (6912 citations) established baseline MRI-clinical integration, revised by Polman et al. (2005) "Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”" (4963 citations) with strengthened evidence, and further updated by Thompson et al. (2017) "Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria" (7511 citations). Wingerchuk et al. (2015) "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders" (4307 citations) builds on these by adding antibody-specific criteria, while Lucchinetti et al. (2000) "Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination" (3304 citations) provides pathological context linking to peripheral processes.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research continues on pathogenesis and intravenous immunoglobulin optimization for Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. No recent preprints or news available, sustaining focus on established diagnostic revisions and antibody associations.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Diagnosis of multiple sclerosis: 2017 revisions of the McDonal... | 2017 | The Lancet Neurology | 7.5K | ✓ |
| 2 | Recommended diagnostic criteria for multiple sclerosis: Guidel... | 2001 | Annals of Neurology | 6.9K | ✕ |
| 3 | Diagnostic criteria for multiple sclerosis: 2005 revisions to ... | 2005 | Annals of Neurology | 5.0K | ✓ |
| 4 | International consensus diagnostic criteria for neuromyelitis ... | 2015 | Neurology | 4.3K | ✓ |
| 5 | A clinical approach to diagnosis of autoimmune encephalitis | 2016 | The Lancet Neurology | 4.2K | ✓ |
| 6 | Axonal Transection in the Lesions of Multiple Sclerosis | 1998 | New England Journal of... | 4.0K | ✓ |
| 7 | Heterogeneity of multiple sclerosis lesions: Implications for ... | 2000 | Annals of Neurology | 3.3K | ✕ |
| 8 | A serum autoantibody marker of neuromyelitis optica: distincti... | 2004 | The Lancet | 3.2K | ✕ |
| 9 | Treatment and prognostic factors for long-term outcome in pati... | 2013 | The Lancet Neurology | 3.0K | ✓ |
| 10 | Multiple Sclerosis | 2000 | New England Journal of... | 2.9K | ✕ |
Frequently Asked Questions
What diagnostic criteria apply to disorders overlapping with peripheral neuropathies?
Thompson et al. (2017) revised the McDonald criteria in "Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria" to demonstrate lesion dissemination in time and space using MRI alongside clinical data. McDonald et al. (2001) introduced guidelines in "Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis" integrating MRI for objective diagnosis. Polman et al. (2005) updated these in "Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”" to strengthen evidence-based assessment.
How are neuromyelitis optica spectrum disorders differentiated from peripheral neuropathies?
Wingerchuk et al. (2015) defined criteria in "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders" based on AQP4-IgG antibodies, optic nerve, and spinal involvement, distinguishing from multiple sclerosis and peripheral conditions. Lennon et al. (2004) identified serum AQP4 autoantibodies in "A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis" as a specific marker absent in most peripheral neuropathy cases.
What pathological features link to peripheral nerve disorders?
Trapp et al. (1998) observed axonal transection in "Axonal Transection in the Lesions of Multiple Sclerosis," correlating with irreversible impairment relevant to demyelinating neuropathies. Lucchinetti et al. (2000) detailed lesion heterogeneity in "Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination," showing varied mechanisms applicable to autoimmune peripheral damage.
What treatments improve outcomes in related autoimmune conditions?
Titulaer et al. (2013) reported in "Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study" that early immunotherapy yields better recovery. Intravenous immunoglobulin serves as a key therapy for Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy per cluster focus.
What is the current state of peripheral neuropathy research?
The field includes 43,064 works on Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, and polyneuropathy. Emphasis remains on pathogenesis, antibody associations, and intravenous immunoglobulin efficacy. No recent preprints or news reported in the last 12 months.
Open Research Questions
- ? How do peripheral demyelinating mechanisms in Guillain-Barré syndrome differ from central lesions in multiple sclerosis?
- ? What specific antibodies beyond AQP4-IgG target peripheral nerves in chronic inflammatory polyradiculoneuropathy?
- ? Which prognostic factors best predict long-term recovery after intravenous immunoglobulin in autoimmune neuropathies?
- ? How can MRI dissemination criteria be adapted for early diagnosis of heterogeneous peripheral neuropathies?
Recent Trends
The field maintains 43,064 papers with no specified 5-year growth rate.
Highly cited works from 1998-2017, such as Thompson et al. with 7511 citations, dominate diagnostics.
2017Absence of recent preprints or news indicates stable emphasis on autoimmune mechanisms and intravenous immunoglobulin therapy.
Research Peripheral Neuropathies and Disorders with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Peripheral Neuropathies and Disorders with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers